Trial Profile
Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Delolimogene mupadenorepvec (Primary)
- Indications Biliary cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Lokon Pharma
- 31 Jan 2024 Planned End Date changed from 1 Dec 2024 to 22 Aug 2024.
- 20 Oct 2023 This trial has been completed (End Date: 22 Aug 2023), according to European Clinical Trials Database record.
- 19 Apr 2023 Results (n=27) presented at the 114th Annual Meeting of the American Association for Cancer Research